Sec Form 4 Filing - Amzak Capital Management, LLC @ Zosano Pharma Corp - 2018-02-26

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Amzak Capital Management, LLC 2. Issuer Name and Ticker or Trading Symbol Zosano Pharma Corp [ ZSAN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 980 N FEDERAL HIGHWAY, SUITE 315 3. Date of Earliest Transaction (MM/DD/YY) 02/26/2018 (Street) BOCA RATON, FL33432 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value of $0.0001 02/26/2018 S 1,500 D $ 11 256,091 D ( 1 ) Common Stock, par value of $0.0001 02/27/2018 S 80,880 D $ 8.357 ( 2 ) 175,211 D ( 1 ) Common Stock, par value of $0.0001 02/27/2018 S 5,901 D $ 8.263 ( 3 ) 0 I Owned by Michael D. Kazma, manager of Amzak Capital Management, LLC

(A) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Amzak Capital Management, LLC 980 N FEDERAL HIGHWAY SUITE 315 BOCA RATON, FL33432 X Kazma Michael D 980 N FEDERAL HIGHWAY SUITE 315 BOCA RATON, FL33432 X Kazma Gerald J 980 N FEDERAL HIGHWAY SUITE 315 BOCA RATON, FL33432 X Signatures AMZAK CAPITAL MANAGEMENT, LLC /s/ Michael Kazma, President 02/28/2018 Signature of Reporting Person Date /s/ Michael D. Kazma 02/28/2018 Signature of Reporting Person Date /s/ Gerald Kazma 02/28/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The securities reported as directly beneficially owned by the Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed on this Form 4, each of whom is a manager of the Reporting Person. ( 2 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.61, inclusive. The Reporting Persons undertake to provide to Zosano Pharma Corp. ("Zosano"), any security holder of Zosano, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in footnotes (2) and (3) of this Form 4. ( 3 )These shares were sold in multiple transactions at prices ranging from $8.20 to $8.35, inclusive.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.